Skip to main content

ADIAL PHARMACEUTICALS INC

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

ADIL$5.05+36.1%Stored close · as of Oct 28, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K for the fiscal year ended December 31, 2023 to be signed on its behalf by the undersigned, thereunto duly authorized, on the 1 stday of April, 2024.

ADIAL PHARMACEUTICALS, INC.
By:/s/ Cary Claiborne
Name:Cary Claiborne
Title:President and Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Cary Claiborne and Joseph Truluck, and each of them, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1934, this Annual Report on Form 10-K has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Cary ClaiborneChief Executive Officer and President
Cary Claiborne(Principal Executive Officer)April 1, 2024
/s/ Joseph M. TruluckChief Financial Officer
Joseph M. Truluck(Principal Financial and Accounting Officer)April 1, 2024
/s/ Kevin Schuyler
Kevin Schuyler, CFAChairman of the Board of DirectorsApril 1, 2024
/s/ J. Kermit Anderson
J. Kermit AndersonMember of the Board of DirectorsApril 1, 2024
/s/ Robertson H. Gilliland
Robertson H. GillilandMember of the Board of DirectorsApril 1, 2024
/s/ Tony Goodman
Tony GoodmanMember of the Board of DirectorsApril 1, 2024
/s/ James W. Newman, Jr.
James W. Newman, JrMember of the Board of DirectorsApril 1, 2024
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.